Roche Acquires Regor’s CDK Inhibitors for $850M to Enhance Breast Cancer Portfolio

Acquisition Details:
Roche, through its subsidiary Genentech, has agreed to acquire Regor Therapeutics' portfolio of next-generation CDK inhibitors for $850 million upfront. The deal includes the Phase I candidate RGT-419B and preclinical candidate RGT-587.

Clinical Development:
Regor will continue to manage the ongoing Phase I trials of RGT-419B until their completion, after which Genentech will take over global clinical development, manufacturing, and commercialization.

Milestone Payments:
Regor is eligible to receive additional cash payments based on the achievement of certain development, regulatory, and commercial milestones.

Strategic Focus:
The acquisition aligns with Roche's strategy to prioritize three therapeutic areas, including oncology, and to develop 20 transformative medicines.

RGT-419B Efficacy:
In Phase I dose escalation studies, RGT-419B showed no dose-limiting toxicity and achieved a 28.6% partial response rate and a 44% clinical benefit rate in HR+/HER2-negative advanced breast cancer patients who had previously undergone CDK4 treatment.

Closing Date:
The proposed transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.